Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG

Company Profile

Country: Germany

Business Type: Trading Company

Mr.Sir
Tel: +49 30 816 96-0

Mobile:
Tel:+49 30 816 96-0
Fax:+49 30 817 40 49
Province/state:
City:
Street:Goerzallee 253 14167 Berlin Germany
MaxCard:

About us

Welcome To Our Site!
HEYL Chemisch-pharmazeutische Fabrik GmbH & Co. KG is an independent, entrepreneurial family business that has its headquarters in probably the liveliest German metropolis, Berlin, since its establishment in 1926. In cooperation with our international subsidiaries, the main focuses of our work are the Regulatory Affairs and marketing of medicines as well as the sale of active pharmaceutical ingredients (API's) and special chemicals.

We concentrate our strengths on special areas and niches. A number of antidotes were developed in cooperation with national and international research institutes and universities. These are highly effective drugs which are used against poisonings by thallium, arsenic, heavy metals (mercury, lead) or by radioactive isotopes like radiocesium or plutonium. Demands from all continents of the world show the uniqueness and medical significance of these drugs.

The active pharmaceutical ingredients (API's) of the antidotes are produced predominantly by Laborchemie Apolda GmbH, our subsidiary firm in Thuringia, according to current quality rules. We are represented in important foreign markets like USA and Japan by our subsidiaries (Heyltex Corporation in Houston, Texas and Heyl Japan & Co. Ltd. in Tokyo). In Berlin, the German and international headquarters join long-standing marketing competence together with medical scientific know-how in five main strategic business fields: antidotes, anti-rheumatics, antibiotics, cod-liver oil preparation and vitamins.

Management and colleagues use their strength to claim our competitiveness by competence and price restraint in the local German market. We want to meet the expectations of our customers and do justice to our responsibility with respect to the families of our colleagues and future capital investors.